Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages. (Q47381165)

From Wikidata

Jump to navigation Jump to search

scientific article published in December 2017

Language	Label	Description	Also known as
English	Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages.	scientific article published in December 2017

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29196953 AND SRC:MED&resulttype=core&format=json

5 April 2020

1 reference

Europe PubMed Central

Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29196953 AND SRC:MED&resulttype=core&format=json

5 April 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29196953 AND SRC:MED&resulttype=core&format=json

5 April 2020

Andreas Katsanos

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29196953 AND SRC:MED&resulttype=core&format=json

5 April 2020

Kostas G Boboridis

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29196953 AND SRC:MED&resulttype=core&format=json

5 April 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29196953 AND SRC:MED&resulttype=core&format=json

5 April 2020

Anastasios G P Konstas

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29196953 AND SRC:MED&resulttype=core&format=json

5 April 2020

author name string

Gábor Holló

1

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29196953

Andreas Katsanos

2

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29196953

Kostas G Boboridis

3

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29196953

Murat Irkec

4

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29196953

Anastasios G P Konstas

5

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29196953

publication date

1 January 2018

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29196953 AND SRC:MED&resulttype=core&format=json

5 April 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29196953 AND SRC:MED&resulttype=core&format=json

5 April 2020

78

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29196953 AND SRC:MED&resulttype=core&format=json

5 April 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29196953 AND SRC:MED&resulttype=core&format=json

5 April 2020

39-64

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29196953 AND SRC:MED&resulttype=core&format=json

5 April 2020

The number of people with glaucoma worldwide in 2010 and 2020

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Management of exfoliative glaucoma: challenges and solutions

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Intraocular pressure as a risk factor for visual field loss in pseudoexfoliative and in primary open-angle glaucoma.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Does adjunctive glaucoma therapy affect adherence to the initial primary therapy?

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Barriers to Glaucoma Medication Compliance Among Veterans: Dry Eye Symptoms and Anxiety Disorders

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

The influence of prior therapy on the success of trabeculectomy

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Preservative exposure and surgical outcomes in glaucoma patients: The PESO study

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Role of fixed combinations in the management of open-angle glaucoma

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Twenty-four hour efficacy of glaucoma medications

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

24-h Efficacy of Glaucoma Treatment Options

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Glaucoma prescribing trends in England 2000 to 2012.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Use of Ocular Hypotensive Medications in Portugal: PEM Study: A Cross-sectional Nationwide Analysis.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Meta-analysis of 24-h intraocular pressure fluctuation studies and the efficacy of glaucoma medicines

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Latanoprost: experience of 2-year treatment in Scandinavia

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

24-hour monitoring of intraocular pressure in glaucoma management: a retrospective review

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

24-hour intraocular pressure and ocular perfusion pressure in glaucoma.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Peak intraocular pressure and glaucomatous progression in primary open-angle glaucoma.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Antiglaucoma medications: a review of safety and tolerability issues related to their use.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Comparison of 24 hour control with Timoptic 0.5% and Timoptic-XE 0.5% in exfoliation and primary open-angle glaucoma.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Fixed combinations of topical glaucoma medications

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin-timolol fixed combinations in primary open-angle glaucoma.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Latanoprost/timolol fixed combination for the treatment of glaucoma.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Therapeutic uses of prostaglandin F(2α) analogues in ocular disease and novel synthetic strategies

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

A review of the use of latanoprost for glaucoma since its launch

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Latanoprost : an update of its use in glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Tafluprost: the first preservative-free prostaglandin to treat open-angle glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Changes in Corneal Biomechanical Properties after Long-Term Topical Prostaglandin Therapy

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Adherence and persistence with glaucoma therapy

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Compliance Barriers in Glaucoma: A Systematic Classification

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Putative side effects of prostaglandin analogs

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

The side effects of the prostaglandin analogues

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Side effects associated with prostaglandin analog therapy

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Prostaglandin analogues in the anterior eye: their pressure lowering action and side effects

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Randomized Clinical Trial of the Efficacy and Safety of Preservative-free Tafluprost and Timolol in Patients With Open-Angle Glaucoma or Ocular Hypertension

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Oculoplastic considerations in patients with glaucoma

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

The Association of Chronic Topical Prostaglandin Analog Use With Meibomian Gland Dysfunction

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Prevalence of ocular surface disease in glaucoma patients

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Commercially available ocular hypotensive products: preservative concentration, stability, storage, and in-life utilization

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Cytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneoconjunctival cell lines

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Ocular surface alteration after long-term treatment with an antiglaucomatous drug

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0. 12% unoprostone

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

TFOS DEWS II Definition and Classification Report.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction: Proceedings of the OCEAN group meeting.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Ocular preservatives: associated risks and newer options

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Allergic reaction to topical eyedrops.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Effects of antiglaucoma drugs on ocular surface.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Quantitative analysis of conjunctival goblet cells after chronic application of topical drops

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Beta-adrenergic receptor blocking drugs: tear lysozyme and immunological screening for adverse reaction

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Tear film osmolarity in patients treated for glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Multiple endpoint analysis of the 3D-reconstituted corneal epithelium after treatment with benzalkonium chloride: early detection of toxic damage.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Effects of topical timolol (0.5%) and betaxolol (0.5%) on corneal sensitivity

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Foreshortening of the inferior conjunctival fornix associated with chronic glaucoma medications

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Effect of benzalkonium chloride on trabecular meshwork cells in a new in vitro 3D trabecular meshwork model for glaucoma.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

One-year efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Preservative-free tafluprost/timolol fixed combination: a new opportunity in the treatment of glaucoma

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Preservatives in eyedrops: the good, the bad and the ugly

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Preservative-free treatment in glaucoma: who, when, and why.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost M

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Trabeculectomy, risk factors for failure and the preoperative state of the conjunctiva

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Pharmacotherapy of glaucoma

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Medical treatment of glaucoma: present and future

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Ocular Surface Disease in Patients with Ocular Hypertension and Glaucoma

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Comparison of a non-preserved 0.1% T-Gel eye gel (single dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patients

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT™) in patients with elevated intraocular pressure in a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Ocular surface changes in glaucomatous patients treated with and without preservatives beta-blockers.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Self-application of single-use eyedrop containers in an elderly population: comparisons with standard eyedrop bottle and with younger patients

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Handling test of eye drop dispenser--comparison of unit-dose pipettes with conventional eye drop bottles.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Preservative-free latanoprost eye drops in patients with primary open-angle glaucoma/ocular hypertension

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted Indirect comparison meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Tear cytokine profile of glaucoma patients treated with preservative-free or preserved latanoprost

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Long-term topical application of preservative-free prostaglandin analogues evokes macrophage infiltration in the ocular adnexa.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Ocular Tolerability of Preservative-Free Tafluprost and Latanoprost: in vitro and in vivo Comparative Study

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Tafluprost: a novel prostaglandin analog for treatment of glaucoma

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Effect of preservative-free tafluprost on keratocytes, sub-basal nerves, and endothelium: a single-blind one-year confocal study on naïve or treated glaucoma and hypertensive patients versus a control group

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on naïve ocular hypertension or glaucoma patients.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Twenty-four-hour ocular hypotensive effects of 0.0015% tafluprost and 0.005% latanoprost in healthy subjects

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

The 24-Hour Effects of Brinzolamide/Brimonidine Fixed Combination and Timolol on Intraocular Pressure and Ocular Perfusion Pressure

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Barriers to glaucoma drug delivery

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Cardiac safety of ophthalmic timolol

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Effect of benzalkonium chloride on transscleral drug delivery

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Effect of preservative removal from fixed-combination bimatoprost/timolol on intraocular pressure lowering: a potential timolol dose-response phenomenon

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Benefits of Tafluprost and Timolol Fixed-Dose Combination for the Treatment of Glaucoma Are Confirmed by Studies on Experimental Animal Models.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Prospective Observational Post-marketing Study of Tafluprost 0.0015%/Timolol 0.5% Combination Ophthalmic Solution for Glaucoma and Ocular Hypertension: Short-Term Efficacy and Safety

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Efficacy of a preservative-free formulation of fixed-combination bimatoprost and timolol (Ganfort PF) in treatment-naïve patients vs previously treated patients.

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Timolol Metabolism in Human Liver Microsomes Is Mediated Principally by CYP2D6

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Unit-dose dispenser tips: a potential source of ocular injury

1 reference

https://api.crossref.org/works/10.1007/S40265-017-0843-9

21 January 2018

Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of timolol, betaxolol, and levobunolol on human tenon's fibroblasts in tissue culture

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of epinephrine and benzalkonium chloride on cultured corneal endothelial and trabecular meshwork cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostaglandin F2 alpha effects on isolated rhesus monkey ciliary muscle

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Clinical evaluation of betaxolol in ophthalmic suspension with or without preservative agent in patients with glaucoma or ocular hypertension]

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A unified theory of the role of the ocular surface in dry eye.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The pathology of dry eye: the interaction between the ocular surface and lacrimal glands

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Compliance and viewpoint of glaucoma patients in Greece

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased human scleral permeability with prostaglandin exposure

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mucocutaneous eruptions, including conjunctiva, due to drug sensitivity; etiological similarity to pemphigus.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007)

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ocular symptoms and signs with preserved and preservative-free glaucoma medications

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Advances in glaucoma management: risk factors, diagnostic tools, therapies and the role of prostaglandin analogs. Foreword

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased likelihood of glaucoma at the same screening intraocular pressure in subjects with pseudoexfoliation: the Thessaloniki Eye Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dry eye syndrome-related quality of life in glaucoma patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topical antiglaucomatous therapy: adverse effects on the conjunctiva and implications for filtration surgery

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparing anatomical pattern of topical anti-glaucoma medications associated lacrimal obstruction with a control group

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bimatoprost and bimatoprost/timolol fixed combination in patients with open-angle glaucoma and ocular hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of benzalkonium chloride- or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ocular Surface Disease and Quality of Life in Patients With Glaucoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of active ingredients and preservatives between brand name and generic topical glaucoma medications using liquid chromatography-tandem mass spectrometry

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circadian intraocular pressure and blood pressure reduction with timolol 0.5% solution and timogel 0.1% in patients with primary open-angle glaucoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Challenges in the clinical measurement of ocular surface disease in glaucoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostaglandin-timolol fixed combinations efficacy: myth or reality?

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Spanish multicenter tafluprost tolerability study

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cell viability score as an integrated indicator for cytotoxicity of benzalkonium chloride-containing antiglaucoma eyedrops.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredients

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term 24-hour intraocular pressure control with travoprost monotherapy in patients with primary open-angle glaucoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intraocular pressure decrease with preservative-free fixed and unfixed combination of tafluprost and timolol in pseudoexfoliative glaucoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Latanoprost in the treatment of glaucoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Excipients of preservative-free latanoprost induced inflammatory response and cytotoxicity in immortalized human HCE-2 corneal epithelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Unpreserved latanoprost in the treatment of open-angle glaucoma and ocular hypertension. A multicenter, randomized, controlled study]

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29196953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40265-017-0843-9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29196953 AND SRC:MED&resulttype=core&format=json

5 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29196953 AND SRC:MED&resulttype=core&format=json

5 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47381165&oldid=2208574083"